Results 81 to 90 of about 1,443,667 (357)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Experimental Hematology & Oncology, 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, Kongming Wu   +6 more
doaj   +1 more source

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. [PDF]

PLoS ONE, 2013
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors).
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, Takehisa Kitazawa, Kazutaka Yoshihashi, Aya Harada, Miho Funaki, Kenta Haraya, Tatsuhiko Tachibana, Sachiyo Suzuki, Keiko Esaki, Yoshiaki Nabuchi, Kunihiro Hattori   +18 more
doaj   +1 more source

Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting

Advanced Materials, EarlyView.
CART cell therapy has proven effective for blood cancers but struggles with solid tumors due to diverse antigens and complex environments. Recent efforts focus on improving CAR design and validation platforms. Advances in protein engineering, machine learning, and organoid systems aim to enhance CAR‐T therapy against solid tumors.
Danqing Zhu, Won Joon Kim, Hyunjin Lee, Xiaoping Bao, Pilnam Kim   +4 more
wiley   +1 more source

CLEC5a-directed bispecific antibody for effective cellular phagocytosis

mAbs, 2022
While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB).
Vivekananda Kedage, Diego Ellerman, Mingjian Fei, Wei-Ching Liang, Gu Zhang, Eric Cheng, Juan Zhang, Yongmei Chen, Haochu Huang, Wyne P. Lee, Yan Wu, Minhong Yan   +11 more
doaj   +1 more source

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Molecular Cancer Therapeutics, 2020
Small molecule inhibitors targeting mutant EGFR are standard of care in non–small cell lung cancer (NSCLC), but acquired resistance invariably develops through mutations in EGFR or through activation of compensatory pathways such as cMet.
S. Vijayaraghavan, L. Lipfert, Kristen M. Chevalier, Barbara S. Bushey, B. Henley, R. Lenhart, J. Sendecki, M. Beqiri, H. Millar, K. Packman, M. V. Lorenzi, S. Laquerre, Sheri L. Moores   +12 more
semanticscholar   +1 more source

Autologous Peripheral Vγ9Vδ2 T Cell Synergizes with αβ T Cell Through Antigen Presentation and BTN3A1 Blockade in Immunotherapy of Cervical Cancer

Advanced Science, EarlyView.
This study provides proof‐of‐concept evidence showing that through direct killing, antigen presentation, and competitively binding to BTN3A1, Vγ9Vδ2 T cells amplified from cervical cancer (CC) patients can synergize with αβ T cells to exert anti‐CC function both in vitro and in vivo.
Min Wu, Jian Liu, Liting Liu, Yifan Yang, Hong Liu, Long Yu, Haihong Zeng, Shuo Yuan, Ruiyi Xu, Hangyu Liu, Han Jiang, Shen Qu, Liming Wang, Ying Chen, Jingyu Wang, Yuwei Zhang, Shan He, Ling Feng, Junyan Han, Wanjiang Zeng, Hui Wang, Yafei Huang   +21 more
wiley   +1 more source

Conditional Activation of Protein Therapeutics by Templated Removal of Peptide Nucleic Acid Masking Groups

Angewandte Chemie, EarlyView.
A strategy for the conditional activation of therapeutic proteins utilizing removable peptide nucleic acid (PNA) masking groups is presented. Site‐specific installation of “Lock”‐PNAs containing a cleavage thioester linkage enabled steric blockage of receptor binding sites.
Bengt H. Gless, Elisabeth Jones, Carlos Labão‐Almeida, Cong Tang, Nicole Gottscheber, Renata Couto, Gonçalo J. L. Bernardes   +6 more
wiley   +2 more sources

GRP78 Nanobody‐Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy

Advanced Science, EarlyView.
A GRP78 nanobody‐directed immunotoxin suppresses cancer progression and metastasis by enhancing antitumor immunity via STING pathway activation, offering a pan‐cancer‐targeted approach and immunotherapy combination strategy. Abstract The lack of targetable antigens poses a significant challenge in developing effective cancer‐targeted therapies.
Huifang Wang, Runhua Zhou, Chengchao Xu, Lingyun Dai, Rui Hou, Liuhai Zheng, Chunjin Fu, Guangwei Shi, Jingwei Wang, Yang Li, Jinpeng Cen, Xiaolong Xu, Le Yu, Yilei Li, Jigang Wang, Qingfeng Du, Zhijie Li   +16 more
wiley   +1 more source

CYTOCON: The manually curated database of human in vivo cell and molecule concentrations

CPT: Pharmacometrics &Systems Pharmacology, Volume 12, Issue 1, Page 41-49, January 2023., 2023
Abstract Cell and cYTOkine CONcentrations DataBase (CYTOCON DB) is a project undertaken by the InSysBio team and aimed at the development of a database that allows collecting, processing, and visualizing publicly available in vivo human data on baseline concentrations of cells, cytokines, chemokines, and other molecules.
Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nail Gizzatkulov, Oleg Demin   +4 more
wiley   +1 more source

Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody [PDF]

, 2020
Broadly neutralizing antibodies are promising candidates for treatment and prevention of HIV-1 infections. Such antibodies can temporarily suppress viral load in infected individuals; however, the virus often rebounds by escape mutants that have evolved resistance.
arxiv   +1 more source